Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 11/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NAPEPLD | Q6IQ20 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121715 | 0.77 | MAPT (0.57) | PIK3CBKMT2ACYP1A2CYP2D6MAPT | |
| SCHEMBL25394278 | 0.77 | PIK3CA (0.42) | PIK3CBPIK3CAPIK3CGMTORPIK3CD | |
| SCHEMBL368719 | 0.76 | ATR (0.48) | PIK3CBPIK3CAPIK3CGMTORPIK3CD | |
| SCHEMBL1029727 | 0.76 | CYP1A2 (0.54) | PIK3CBPIK3CAKMT2ACYP1A2CYP2D6 | |
| SCHEMBL3596067 | 0.76 | KMT2A (0.48) | PIK3CBPIK3CAPIK3CGMTORKMT2A | |
| SCHEMBL3125978 | 0.75 | CYP1A2 (0.59) | PIK3CBPIK3CAKMT2ACYP1A2CYP2D6 | |
| SCHEMBL14042944 | 0.73 | CYP1A2 (0.45) | KMT2ANAPEPLDCYP1A2CYP2D6MAPT | |
| SCHEMBL3598677 | 0.72 | ALDH1A1 (0.46) | PIK3CAPIK3CGMTORKMT2AMAPT | |
| SCHEMBL4107176 | 0.70 | PIK3CA (0.51) | PIK3CBPIK3CAPIK3CGMTORPIK3CD | |
| SCHEMBL18739162 | 0.70 | PIK3CB (0.67) | PIK3CBPIK3CAPIK3CGMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150546-B1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2150546-B1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIK3CA, PIP5K1B, PIK3CD | PIK3CB 5/4885PIK3CA 1/4885PIK3CG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.